[go: up one dir, main page]

IL163673A0 - Farnesyl protein transferase inhibitors as antitumor agents - Google Patents

Farnesyl protein transferase inhibitors as antitumor agents

Info

Publication number
IL163673A0
IL163673A0 IL16367303A IL16367303A IL163673A0 IL 163673 A0 IL163673 A0 IL 163673A0 IL 16367303 A IL16367303 A IL 16367303A IL 16367303 A IL16367303 A IL 16367303A IL 163673 A0 IL163673 A0 IL 163673A0
Authority
IL
Israel
Prior art keywords
protein transferase
antitumor agents
transferase inhibitors
farnesyl protein
farnesyl
Prior art date
Application number
IL16367303A
Other languages
English (en)
Original Assignee
Schering Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/085,896 external-priority patent/US20030229099A1/en
Application filed by Schering Corp filed Critical Schering Corp
Publication of IL163673A0 publication Critical patent/IL163673A0/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D221/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
    • C07D221/02—Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00 condensed with carbocyclic rings or ring systems
    • C07D221/04—Ortho- or peri-condensed ring systems
    • C07D221/06—Ring systems of three rings
    • C07D221/16—Ring systems of three rings containing carbocyclic rings other than six-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
    • C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL16367303A 2002-02-27 2003-02-25 Farnesyl protein transferase inhibitors as antitumor agents IL163673A0 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US10/085,896 US20030229099A1 (en) 2000-08-30 2002-02-27 Novel farnesyl protein transferase inhibitors as antitumor agents
US10/325,896 US7342016B2 (en) 2000-08-30 2002-12-19 Farnesyl protein transferase inhibitors as antitumor agents
PCT/US2003/005479 WO2003072549A1 (fr) 2002-02-27 2003-02-25 Inhibiteurs de la farnesyl proteine transferase en tant qu'agents antitumoraux

Publications (1)

Publication Number Publication Date
IL163673A0 true IL163673A0 (en) 2005-12-18

Family

ID=27767345

Family Applications (1)

Application Number Title Priority Date Filing Date
IL16367303A IL163673A0 (en) 2002-02-27 2003-02-25 Farnesyl protein transferase inhibitors as antitumor agents

Country Status (19)

Country Link
US (1) US7342016B2 (fr)
EP (1) EP1492772A1 (fr)
JP (1) JP2005525356A (fr)
KR (1) KR20040098004A (fr)
CN (1) CN100537542C (fr)
AR (1) AR039557A1 (fr)
AU (1) AU2003215389B2 (fr)
BR (1) BR0308071A (fr)
CA (1) CA2477328A1 (fr)
CO (1) CO5611194A2 (fr)
IL (1) IL163673A0 (fr)
MX (1) MXPA04008303A (fr)
NO (1) NO20044053L (fr)
NZ (1) NZ534809A (fr)
PE (1) PE20031038A1 (fr)
PL (1) PL372335A1 (fr)
RU (1) RU2004128465A (fr)
TW (1) TW200303867A (fr)
WO (1) WO2003072549A1 (fr)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS20050885A (sr) * 2003-05-30 2008-04-04 Genentech Lečenje sa anti-vegf antitelima
EP1660477B1 (fr) * 2003-08-07 2008-12-10 Schering Corporation Nouveaux inhibiteurs de farnesyl proteine transferase comme agents antitumoraux
EP1753429A1 (fr) * 2004-05-28 2007-02-21 Vertex Pharmaceuticals Incorporated Modulateurs de récepteurs muscariniques
ATE412651T1 (de) 2004-06-09 2008-11-15 Glaxo Group Ltd Pyrrolopyridinderivate
MX2007007078A (es) 2004-12-14 2007-09-04 Schering Corp Inhibidores de farnesil-transferasa de proteina y metodos para tratar las enfermedades proliferativas.
KR20070090943A (ko) * 2004-12-21 2007-09-06 쉐링 코포레이션 항종양제로서 신규한 파르네실 단백질 트랜스퍼라제 억제제
CN101400656A (zh) * 2006-01-19 2009-04-01 先灵公司 作为法呢基蛋白转移酶抑制剂的哌嗪衍生物
WO2008054598A2 (fr) * 2006-09-29 2008-05-08 Schering Corporation Panel de biomarqueurs pour prévision d'efficacité fti
CN103143017A (zh) * 2006-12-19 2013-06-12 基因技术公司 用于辅助和新辅助疗法以及早期肿瘤的治疗的vegf特异性拮抗剂
WO2010006432A1 (fr) 2008-07-14 2010-01-21 Queen's University At Kingston Compositions pharmaceutiques contenant des inhibiteurs de ret et procédés de traitement du cancer
WO2010107739A2 (fr) 2009-03-18 2010-09-23 The Board Of Trustees Of The Leland Stanford Junior University Méthodes et compositions pour traiter l'infection par un virus de la famille des flaviviridae
US9187454B2 (en) * 2013-03-13 2015-11-17 Boston Biomedical, Inc. Inhibitors of kinases and cancer stem cells, and methods of preparation and use thereof
US9227962B2 (en) 2013-03-13 2016-01-05 Boston Biomedical, Inc. Heterocyclic substituted-3-heteroarylidenyl-2-indolinone derivative
CN105777646A (zh) * 2016-04-08 2016-07-20 西南科技大学 一种新的5-碘-2-苯基-1-甲基咪唑的制备方法
CN111454329A (zh) * 2020-04-07 2020-07-28 哈尔滨师范大学 一种具有抗癌活性的异茚哚酮桥连环九肽及其制备方法
CN115385892A (zh) * 2021-10-28 2022-11-25 天津市昕晨投资发展有限公司 地氯雷他定衍生物、其制备方法及其用途

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4826853A (en) 1986-10-31 1989-05-02 Schering Corporation 6,11-Dihydro-11-(N-substituted-4-piperidylidene)-5H-benzo(5,6)cyclohepta(1,2-B)pyridines and compositions and methods of use
US5089496A (en) * 1986-10-31 1992-02-18 Schering Corporation Benzo[5,6]cycloheptapyridine compounds, compositions and method of treating allergies
US5393890A (en) * 1988-06-02 1995-02-28 Ajinomoto Co., Inc. Piperidine derivatives and hypotensives containing the same
AU8854091A (en) * 1990-10-10 1992-05-20 Schering Corporation Bis-benzo cyclohepta piperidylidene, piperidine and piperazine compounds, compositions and methods of use
GB9513371D0 (en) 1995-06-30 1995-09-06 Biocine Spa Immunogenic detoxified mutant toxins
US5643909A (en) 1993-04-19 1997-07-01 Syntex (U.S.A.) Inc. 10,11-Methanodibenzosuberane derivatives
US6075025A (en) * 1993-10-15 2000-06-13 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
US5719148A (en) * 1993-10-15 1998-02-17 Schering Corporation Tricyclic amide and urea compounds useful for inhibition of g-protein function and for treatment of proliferative diseases
US5721236A (en) * 1993-10-15 1998-02-24 Schering Corporation Tricyclic carbamate compounds useful for inhibition of G-protein function and for treatment of proliferative diseases
IL111235A (en) * 1993-10-15 2001-03-19 Schering Plough Corp Medicinal preparations for inhibiting protein G activity and for the treatment of malignant diseases, containing tricyclic compounds, some such new compounds and a process for the preparation of some of them
US5874442A (en) * 1995-12-22 1999-02-23 Schering-Plough Corporation Tricyclic amides useful for inhibition of G-protein function and for treatment of proliferative disease
WO1997023478A1 (fr) * 1995-12-22 1997-07-03 Schering Corporation Amides tricycliques destines a l'inhibition de la fonction de la proteine-g et au traitement des maladies proliferatives
US5861395A (en) * 1996-09-13 1999-01-19 Schering Corporation Compounds useful for inhibition of farnesyl proteins transferase
EP0929544B1 (fr) 1996-09-13 2004-11-10 Schering Corporation Composes antitumoraux tricycliques inhibiteurs de la farnesyl transferase proteique
US6071907A (en) * 1996-09-13 2000-06-06 Schering Corporation Tricyclic compounds useful as FPT inhibitors
CA2265764A1 (fr) * 1996-09-13 1998-03-19 Schering Corporation Composes tricycliques servant a inhiber la farnesyl-proteine transferase
GB9801231D0 (en) * 1997-06-05 1998-03-18 Merck & Co Inc A method of treating cancer
CN1267291A (zh) 1997-06-17 2000-09-20 先灵公司 新的n－取代的脲的法呢基蛋白转移酶抑制剂
TR200000114T2 (tr) 1997-06-17 2000-08-21 Schering Corporation Farnesil protein transferazı'nın önlenmesine mahsus benzo(5,6)siklohepta(1,2-B)piridin türevleri.
PE104798A1 (es) 1997-06-17 1999-11-06 Pharmacopeia Inc Compuestos utiles para la inhibicion de la enzima farnesilo transferasa
CN1267290A (zh) 1997-06-17 2000-09-20 先灵公司 新的法呢基－蛋白转移酶的三环磺酰胺抑制剂
US5925648A (en) * 1997-07-29 1999-07-20 Schering Corporation Tricyclic N-cyanoimines useful as inhibitors of a farnesyl-protein transferase
IL143408A0 (en) 1998-12-18 2002-04-21 Schering Corp Tricyclic farnesyl protein transferase inhibitors
JP2002533335A (ja) 1998-12-18 2002-10-08 シェーリング コーポレイション ファルネシルタンパク質トランスフェラーゼインヒビター
AU2292801A (en) * 1999-12-22 2001-07-03 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Compositions and methods for treatment of breast cancer
SI1255537T1 (sl) 2000-02-04 2006-10-31 Janssen Pharmaceutica Nv Inhibitorji farnezil protein transferaze za zdravljenje raka dojk
AR033680A1 (es) 2000-08-30 2004-01-07 Schering Corp Compuestos triciclicos utiles como inhibidores de la farnesil proteino transferasa y su uso para la manufactura de medicamentos como agentes antitumorales
EP1453513A1 (fr) * 2001-12-03 2004-09-08 Schering Corporation Procede servant a traiter le cancer au moyen d'inhibiteurs de fpt et d'agents antineoplasiques
EP1660477B1 (fr) * 2003-08-07 2008-12-10 Schering Corporation Nouveaux inhibiteurs de farnesyl proteine transferase comme agents antitumoraux

Also Published As

Publication number Publication date
BR0308071A (pt) 2004-12-21
AU2003215389A1 (en) 2003-09-09
AR039557A1 (es) 2005-02-23
KR20040098004A (ko) 2004-11-18
PL372335A1 (en) 2005-07-11
MXPA04008303A (es) 2005-11-23
TW200303867A (en) 2003-09-16
NO20044053L (no) 2004-11-26
US20040122018A1 (en) 2004-06-24
CN1630641A (zh) 2005-06-22
US7342016B2 (en) 2008-03-11
CA2477328A1 (fr) 2003-09-04
EP1492772A1 (fr) 2005-01-05
PE20031038A1 (es) 2004-01-10
RU2004128465A (ru) 2005-09-27
CO5611194A2 (es) 2006-02-28
JP2005525356A (ja) 2005-08-25
AU2003215389B2 (en) 2007-10-18
NZ534809A (en) 2007-12-21
CN100537542C (zh) 2009-09-09
WO2003072549A1 (fr) 2003-09-04

Similar Documents

Publication Publication Date Title
EG25482A (en) Inhibitors
IL173380A0 (en) Pyridinylamino-pyrimidine derivatives as protein kinase inhibitors
IL208520A0 (en) Akt protein kinase inhibitors
AU2003254053A8 (en) Pyrazolopyrimidines as protein kinase inhibitors
SI1567112T1 (sl) Thiazolidin-4-oni za inhibiranje proteinov hyak3
AU2003293356A8 (en) Dihydropyridinone derivatives as hne inhibitors
IL163673A0 (en) Farnesyl protein transferase inhibitors as antitumor agents
AU2001235496A1 (en) Farnesyl protein transferase inhibitor combinations with anti-tumor alkylating agents
IL173514A0 (en) Novel farnesyl protein transferase inhibitors as antitumor agents
EP1532133A4 (fr) Inhibiteurs de nf-:b
AU2001252147A1 (en) Farnesyl protein transferase inhibitor combinations
IL154528A0 (en) Tricyclic antitumor compounds being farnesyl protein transferase inhibitors
GB0207362D0 (en) Chemotherapy
ZA200409691B (en) Heterotricyclyl 6-alkylidene-penems as ß-lactamase inhibitors
ZA200705126B (en) Novel farnesyl protein transferase inhibitors as antitumor agents
PL355887A1 (en) Farnesyl transferase inhibitors
GB0311195D0 (en) Glyoxalase inhibitors
AU3514302A (en) 0ovel farnesyl protein transferase inhibitors
AU2003246091A8 (en) Mkk7 activation inhibitor
AU2003232362A8 (en) 4-pyrazol-phenylalanine derivatives as ace-nep inhibitors
AU2003233605A8 (en) Mitogen activated protein kinase inhibitor compositions for lymphoma therapy
HK1106233A (en) Novel farnesyl protein transferase inhibitors as antitumor agents
AU2002250898A1 (en) Farnesyl protein transferase inhibitor combinations with antiestrogen agents
GB0311194D0 (en) Glyoxalase i inhibitors
GB0206031D0 (en) Inhibitors